EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 4, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing (877)-312-7507 for domestic calls or (631)-813-4828 for international calls, using conference ID 1861354. The event will also be available via a live audio webcast on the company’s website. EyePoint is focused on innovative therapeutics for serious eye disorders and utilizes its proprietary Durasert® technology for extended drug delivery.
- None.
- None.
WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 4, 2021 to report its second quarter 2021 financial results and discuss recent business highlights.
To access the live conference call, please dial (877)-312-7507 (domestic) or (631)-813-4828 (international) and reference conference ID 1861354. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.
Investors:
Christina Tartaglia
Stern IR
Direct: (212)-698-8700
christina.tartaglia@sternir.com
Media Contact:
Caren Begun
Green Room Communications
Direct: (201)-396-8551
caren@greenroompr.com
FAQ
What financial results will EyePoint Pharmaceuticals report on August 4, 2021?
How can I listen to the EyePoint Pharmaceuticals conference call?
What is EYPT's focus in the pharmaceutical market?
What technology does EyePoint Pharmaceuticals use for drug delivery?
